BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 31914417)

  • 1. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose.
    Joly JH; Delfarah A; Phung PS; Parrish S; Graham NA
    J Biol Chem; 2020 Jan; 295(5):1350-1365. PubMed ID: 31914417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
    Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death.
    Banjac A; Perisic T; Sato H; Seiler A; Bannai S; Weiss N; Kölle P; Tschoep K; Issels RD; Daniel PT; Conrad M; Bornkamm GW
    Oncogene; 2008 Mar; 27(11):1618-28. PubMed ID: 17828297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redox-dependent AMPK inactivation disrupts metabolic adaptation to glucose starvation in xCT-overexpressing cancer cells.
    Lee Y; Itahana Y; Ong CC; Itahana K
    J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35775474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation.
    Goji T; Takahara K; Negishi M; Katoh H
    J Biol Chem; 2017 Dec; 292(48):19721-19732. PubMed ID: 29038291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11).
    Yamaguchi I; Yoshimura SH; Katoh H
    J Biol Chem; 2020 May; 295(20):6936-6945. PubMed ID: 32265299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis for redox control by the human cystine/glutamate antiporter system xc
    Parker JL; Deme JC; Kolokouris D; Kuteyi G; Biggin PC; Lea SM; Newstead S
    Nat Commun; 2021 Dec; 12(1):7147. PubMed ID: 34880232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.
    Koppula P; Zhang Y; Shi J; Li W; Gan B
    J Biol Chem; 2017 Aug; 292(34):14240-14249. PubMed ID: 28630042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
    Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
    Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification, Expression, and Roles of the Cystine/Glutamate Antiporter in Ocular Tissues.
    Martis RM; Knight LJ; Donaldson PJ; Lim JC
    Oxid Med Cell Longev; 2020; 2020():4594606. PubMed ID: 32655769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
    Koppula P; Zhuang L; Gan B
    Protein Cell; 2021 Aug; 12(8):599-620. PubMed ID: 33000412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer.
    Liu X; Olszewski K; Zhang Y; Lim EW; Shi J; Zhang X; Zhang J; Lee H; Koppula P; Lei G; Zhuang L; You MJ; Fang B; Li W; Metallo CM; Poyurovsky MV; Gan B
    Nat Cell Biol; 2020 Apr; 22(4):476-486. PubMed ID: 32231310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
    Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
    Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
    Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
    Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cystine/glutamate antiporter xCT is a key regulator of EphA2 S897 phosphorylation under glucose-limited conditions.
    Teramoto K; Katoh H
    Cell Signal; 2019 Oct; 62():109329. PubMed ID: 31152846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-) : cystine supplier and beyond.
    Conrad M; Sato H
    Amino Acids; 2012 Jan; 42(1):231-46. PubMed ID: 21409388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hijacking microglial glutathione by inorganic arsenic impels bystander death of immature neurons through extracellular cystine/glutamate imbalance.
    Singh V; Gera R; Kushwaha R; Sharma AK; Patnaik S; Ghosh D
    Sci Rep; 2016 Aug; 6():30601. PubMed ID: 27477106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
    Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
    Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
    Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
    Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc
    Guo W; Li K; Sun B; Xu D; Tong L; Yin H; Liao Y; Song H; Wang T; Jing B; Hu M; Liu S; Kuang Y; Ling J; Li Q; Wu Y; Wang Q; Yao F; Zhou BP; Lin SH; Deng J
    Cancer Res; 2021 Feb; 81(3):552-566. PubMed ID: 33229341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.